InformationClinical trials have complex eligibility criteria.
Always talk to your clinician about you’re interest in participating in a trial.
Learn why

Optimise reading forHealth ProfessionalsPatients

RecruitingLast updated:24 July 2023

SHERLOCK: This phase II study is testing the effectiveness of a new treatment combination (sotorasib, carboplatin-pemetrexed, and bevacizumab-biosimilar) for people with non-small cell lung cancer whose cancer has a specific type of gene mutation called KRAS G12CPhase 2 trial of sotorasib in combination with carboplatin-pemetrexed and bevacizumab-biosimilar as first line treatment for advanced non-squamous non-small cell lung cancer with KRAS G12C mutation

Clinical summary

Summary

Eligible participants will all receive treatment with targeted therapy (sotorsib and bevacizumab-biosimilar) and combination chemotherapy (carboplatin-pemetrexed). Treatment will be given in two stages: Induction and Maintenance. The Induction stage consists of 4 x 3 weekly cycles of sotorasib (960mg, oral tablets daily) plus pemetrexed (500mg/m2 on Day 1 every 3 weeks via intravenous infusion) plus carboplatin (total dose not exceeding 750mg and calculated for each participant using the Calvert method, on Day 1 every 3 weeks via intravenous infusion) plus bevacizumab-biosimilar (15mg/kg, Day 1 every 3 weeks via intravenous infusion). In the Maintenance stage, participants will receive sotorasib (960mg, oral tablets daily) plus Pemetrexed (500mg/m2 on Day 1 every 3 weeks via intravenous infusion ) plus bevacisumab-biosimilar (15mg/kg, Day 1 every 3 weeks via intravenous infusion).

Age

People8+

Phase

II

Trial Acronym

SHERLOCK

More information

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Commercial Sponsor

AMGEN, University of Sydney, Thoracic Oncology Group of Australasia

Scientific Title

Phase 2 trial of sotorasib in combination with carboplatin-pemetrexed and bevacizumab-biosimilar as first line treatment for advanced non-squamous non-small cell lung cancer with KRAS G12C mutation

Eligibility

Inclusion

  • You have certain types of non-cancer medical conditions.
  • You have been diagnosed with a prior or secondary type of cancer.
  • You have had certain treatments, surgical procedures or drugs.
  • You have previously been treated (or are currently being treated) on a clinical trial.

Exclusion

  • You are able to swallow medication by mouth.
  • You have been diagnosed with cancer, but have not received any treatment.
  • You have had treatment, but your cancer has come back.
  • Your cancer has spread to other parts of the body.
Message

Clinical trials have complex eligibility criteria.

Ask your doctor if this trial could be right for you.

Participating hospitals

Recruiting hospitals

InformationTell us if you find this trial availability is not accurate.Report inaccuracy

Get Support

Example

Cancer Connect

Speak with someone who has cancer clinical trial experience.

Learn more

Example

Cancer Council’s cancer nurses

If you need cancer information and practical support for yourself, a carer, family or friend, contact Cancer Council’s experienced cancer nurses on 131120.

Learn more

Example

Information for family, friends and carers

When you are considering a cancer clinical trial, it is a good idea to discuss it with your family, friends or carers.

Learn more